journal Journal For International Medical Graduates Journal For International Medical Graduates California Institute of Behavioral Neurosciences and Psychology US https://www.cibnp.com 2832-9864 149 Articles Role of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitor Therapy in Treatment of Patients With Polycystic Ovary Syndrome: A Systemic Review of Metabolic and Cardiovascular Outcomes Dev Patel Patel Dev devpatel1618@gmail.com Jabez John John Jabez jabez.john@jimgs.com Ranita Bodepudi Bodepudi Ranita ranita.bodepudi@jimgs.com Saniya Seher Seher Saniya saniya.seher@jimgs.com Shenel Khan Khan Shenel shenel.khan@jimgs.com Soniya Emmanuel Emmanuel Soniya soniya.emmanuel@jimgs.com Vivig Shantha Shantha Vivig vivig.shantha@jimgs.com Resheek Nerella Nerella Resheek resheek.nerella@jimgs.com Basim Shaman Shaman Basim basim.shaman@jimgs.com Pousette Hamid Hamid Pousette pousette.hamid@jimgs.com California Institute of Behavioural Neurosciences & Psychology 19 02 2024 Received: 1922024 Copyright (c) 2024 Journal For International Medical Graduates 2024 Journal For International Medical Graduates Polycystic Ovary Syndrome (PCOS) PCSK9 inhibitors Dyslipidemia management Cardio-metabolic complications Statins vs. PCSK9 efficacy Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 1. Endocrine Practice. 2015;21(11):1291-1300. doi:https://doi.org/10.4158/ep15748.dsc What are the symptoms of PCOS? https://www.nichd.nih.gov/. Published January 31, 2017. https://www.nichd.nih.gov/health/topics/pcos/conditio ninfo/symptoms Crespo RP, Bachega TASS, Mendonça BB, Gomes LG. An update of genetic basis of PCOS pathogenesis. Archives of Endocrinology and Metabolism. 2018;62(3):352-361.doi:https://doi.org/10.20945/2359-3997000000049 What We Talk About When We Talk About PCOS. www.vice.com. https://www.vice.com/en/article/zmae5j/what-we-talk-about-when-we-talk-about-pcos About Polycystic Ovary Syndrome (PCOS). https://www.nichd.nih.gov/. https://www.nichd.nih.gov/health/topics/pcos/conditio ninfo Dawood A, Goyal M. Debates regarding lean patients with polycystic ovary syndrome: A narrative review. Journal of Human Reproductive Sciences. 2017;10(3):154.doi:https://doi.org/10.4103/jhrs.jhrs_77_17 Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2013;98(12):4565-4592.doi:https://doi.org/10.1210/jc.2013-2350 Polycystic Ovarian Syndrome Treatment & Management: Approach Considerations, Lifestyle Modifications, Drug Treatment. Medscape.com. Published September 16, 2018. https://emedicine.medscape.com/article/256806-treatment Huang G, Coviello A. Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. Current Opinion in Endocrinology & Diabetes and Obesity. 2012;19(6):512-519. doi:https://doi.org/10.1097/med.0b013e32835a000e Wang FF, Wu Y, Zhu YH, et al. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Obesity Reviews. 2018;19(10):1424-1445.doi:https://doi.org/10.1111/obr.12720 Liu Q, Xie Y, Qu L, Zhang M, Mo Z. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwanese Journal of Obstetrics and Gynecology. 2019;58(4):447-453.doi:https://doi.org/10.1016/j.tjog.2019.05.003 Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertility and Sterility. 2011;95(3):1073-1079.e11.doi:https://doi.org/10.1016/j.fertnstert.2010.12.027 Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Human Reproduction Update. 2020;26(6):942-960. doi:https://doi.org/10.1093/humupd/dmaa029 Zhu S, Zhang B, Jiang X, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and Sterility. 2019;111(1):168-177. doi:https://doi.org/10.1016/j.fertnstert.2018.09.013 Zhao L, Zhu Z, Lou H, et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget. 2016;7(23):33715-33721.doi:https://doi.org/10.18632/oncotarget.9553 Yanes L, Romero DG, Reckelhoff JF. Cardiometabolic Features of Polycystic Ovary Syndrome: Role of Androgens. Physiology. 2017;32(5):357-366. doi:https://doi.org/10.1152/physiol.00030.2016 Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends in Cardiovascular Medicine. 2020;30(7):399-404. doi:https://doi.org/10.1016/j.tcm.2019.08.010 Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Molecular Metabolism. 2020;35:100937. doi:https://doi.org/10.1016/j.molmet.2020.01.001 Yang R, Yang S, Li R, Liu P, Qiao J, Zhang Y. Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis. Reproductive Biology and Endocrinology. 2016;14(1). doi:https://doi.org/10.1186/s12958-016-0203-8 Valkenburg O, R.P.M. Steegers‐Theunissen, H.P.M. Smedts, et al. A More Atherogenic Serum Lipoprotein Profile Is Present in Women with Polycystic Ovary Syndrome: A Case-Control Study. The Journal of Clinical Endocrinology and Metabolism. 2008;93(2):470-476. doi:https://doi.org/10.1210/jc.2007-1756 Zhang Y, Suo Y, Yang L, et al. Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis. Cardiology Research and Practice. 2022;2022:1-13.doi:https://doi.org/10.1155/2022/8729003 Bergeron N, Phan BAP, Ding Y, Fong A, Krauss RM. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. Circulation. 2015;132(17):1648-1666. doi:https://doi.org/10.1161/circulationaha.115.016080 Li C, Lin L, Zhang W, et al. Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials. 2015;4(6). doi:https://doi.org/10.1161/jaha.115.001937 Bär S, Räber I, Koskinas KC, Christoph Schlapbach, Lorenz Räber. Transient injection site reaction to alirocumab during immune system activation: a case series. European Heart Journal - Case Reports. 2022;6(5). doi:https://doi.org/10.1093/ehjcr/ytac187 di Mauro G, Zinzi A, Scavone C, et al. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. Drug Safety. 2020;44(3):337-349.doi:https://doi.org/10.1007/s40264-020-01021-3 Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 2016;316(7):743.doi:https://doi.org/10.1001/jama.2016.11004 Kosmas CE, Skavdis A, Sourlas A, et al. Safety and Tolerability of PCSK9 Inhibitors: Current Insights. Clinical Pharmacology : Advances and Applications. 2020;12:191-202. doi:https://doi.org/10.2147/CPAA.S288831 amilial Hypercholesterolemia and Pregnancy. American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2018/05/10/13/51/familial-hypercholesterolemia-and-pregnancy#:~:text=PCSK9%20inhibitors%20have%2 0not%20been Wang M, Zhao D, Xu L, et al. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome. Metabolism. 2019;94:47-58. doi:10.1016/j.metabol.2019.02.002 Bizoń A, Franik G, Madej P. The role of proprotein convertase subtilisin/kexin type-9 concentration and paraoxonase 1 activities in the blood of women with polycystic ovary syndrome. Environ Toxicol Pharmacol. 2021;84:103612. doi:10.1016/j.etap.2021.103612 Moazzeni DR. PCSK9 Inhibitors: The New Frontier in Cholesterol Management. Heartcare Sydney. Published August 20, 2023. https://heartcare.sydney/pcsk9-inhibitors/ Schulz R, Andreadou I, Ferdinandy P. Editorial: PCSK9: Importance in Physiology and Pathophysiology. Frontiers in Physiology. 2021;12. doi:https://doi.org/10.3389/fphys.2021.706115